Bullish case
$78 to $83
More likely if Growth Portfolio revenue compounds, Eliquis remains resilient, pivotal pipeline readouts are positive, debt continues to decline, and the market values BMY near 12x earnings.
Bristol Myers Squibb Company research snapshot
BMY AI Stock Analysis
BMY AI stock analysis currently reads Bristol Myers Squibb Company as a mature large-cap biopharma company trying to convert a legacy-drug patent cliff into a growth-portfolio recovery. At the July 8, 2026 data cutoff, BMY traded near $57.97 with an implied market capitalization of about $118.38 billion. The setup has strong cash flow, a high dividend yield, and visible growth from Camzyos, Breyanzi, Reblozyl, and newer medicines, but it also carries Revlimid erosion, Eliquis concentration, debt, and pipeline execution risk. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$57.97
Market cap
$118.38 billion
AI score
67 / 100
Rating
Cash-rich pharma transition story, execution watch
Trend status
Constructive short-term trend with patent-cycle overhang
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Bristol Myers Squibb has long public filings, detailed product revenue tables, quarterly releases, proxy data, analyst coverage, and broad technical data.
- bias Check
- The main AI bias risk is accepting the growth-portfolio recovery narrative too quickly while under-weighting legacy erosion, Eliquis policy risk, acquisition debt, patent loss cycles, and binary clinical data.
- ai Confidence
- High for filings, Q1 2026 reported metrics, share-count math, valuation calculations, and technical snapshots. Medium for forward valuation because drug approvals, pricing policy, trial results, and patent disputes can reprice the stock quickly.
- investment Certainty
- Medium. The cash flow and valuation are measurable, but the long-term thesis depends on pipeline replacement power and disciplined capital allocation.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bristol Myers Squibb sells patented medicines for oncology, hematology, cardiovascular, immunology, neuroscience, and rare disease markets. | High |
| Moat | The moat comes from patents, clinical evidence, physician trust, payer access, regulatory expertise, global sales scale, and manufacturing know-how. | Medium-high |
| Management | Chris Boerner is managing a portfolio transition with R&D focus, business development, debt reduction, and shareholder returns as the key capital allocation tests. | Medium |
| Financial trend | FY2025 revenue was $48.194 billion and Q1 2026 revenue rose 3% to $11.489 billion as Growth Portfolio strength offset legacy erosion. | High |
| Valuation | At $57.97, BMY traded near 9.35x 2026 non-GAAP EPS guidance midpoint, 9.94x free cash flow per share, and a 4.35% dividend yield. | Medium-high |
| Technical trend | Daily technical signals were constructive, with price above the 50-day and 200-day moving averages and RSI in a neutral-to-positive zone. | Medium |
| Risk level | Main risks are patent cliffs, Eliquis policy and competition, failed clinical assets, acquisition integration, leverage, pricing pressure, and regulatory setbacks. | Medium-high |
| AI confidence | High for descriptive research and audited calculations. Lower for exact price outcomes because pharma stocks can move sharply around trial and regulatory events. | High data confidence |
| Investment certainty | Medium certainty. BMY looks inexpensive on forward non-GAAP earnings, but that discount reflects real replacement-cycle risk. | Medium |
BMY AI stock forecast
BMY AI Stock Forecast Scenarios
The BMY AI stock forecast uses scenario math around the $57.97 quote and Bristol Myers Squibb 2026 non-GAAP EPS guidance midpoint of $6.20. The audited three-year framework produced a bearish area near $37, a base area near $62, and a bullish area near $81 before dividends.
Base case
$60 to $64
More likely if EPS holds near the 2026 guidance base, growth products offset most legacy erosion, and investors keep the stock near a 10x earnings multiple.
Bearish case
$36 to $39
More likely if Revlimid and other legacy declines accelerate, Eliquis pricing or competition worsens, pipeline assets disappoint, or leverage and patent risk drive the multiple toward 7x earnings.
BMY AI technical analysis
BMY AI Technical Analysis
BMY AI technical analysis is constructive as of the July 8, 2026 cutoff. Investing.com reported a strong buy daily technical condition, a 50-day moving average near $57.39, a 200-day moving average near $56.35, and a 14-day RSI near 56.43. StockAnalysis listed a similar price snapshot at the July 7, 2026 close.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $57.97 | StockAnalysis close on July 7, 2026, used for market cap and valuation math. |
| Near support | $56.35 to $57.39 | The 200-day and 50-day moving averages form the nearest technical support band. |
| Secondary support | $54.69 to $55.21 | ChartMill identified this as a support zone formed by trend lines and moving averages. |
| Near resistance | $58 to $63 | A clean move above the recent quote zone would put the average analyst target near $63 in focus. |
| 50-day moving average | $57.39 | Investing.com listed the 50-day moving average as a buy signal. |
| 200-day moving average | $56.35 | Price was above the long-term average, supporting a constructive trend reading. |
| Momentum | 14-day RSI 56.43 | RSI was positive but not extreme, leaving room for either continuation or a failed breakout. |
| Volume | 20-day average about 13.3 million shares | StockAnalysis reported liquid large-cap trading volume at the July 7, 2026 check. |
| Volatility | Low-beta pharma volatility | Beta was listed near 0.24, but drug-specific events can still cause sudden gaps. |
| Invalidation | Close below $56, then $54 | A decisive break below the 200-day average would weaken the technical setup. A break below the lower support zone would be more serious. |
BMY AI trading strategy
BMY AI Trading Strategy Framework
The BMY AI trading strategy is a rules-based research framework for a discounted biopharma transition story. It is not personal advice and should be paired with live quotes, filings, position sizing, FDA and clinical event checks, and portfolio-level risk limits.
Trend-following setup
Watch for BMY to hold above the 50-day and 200-day moving averages and break above the $58 area with volume confirmation.
A close below $56 or a failed breakout after earnings should invalidate the short-term trend setup.
Mean-reversion setup
If BMY pulls back toward $55 without a new product, trial, or guidance problem, compare the selloff with cash flow, dividend coverage, and Growth Portfolio evidence.
Do not average down without a defined loss limit because patent and trial news can turn a support level into a thesis break.
Fundamental monitor
Track Growth Portfolio revenue, Eliquis growth and pricing, Revlimid erosion, non-GAAP EPS guidance, free cash flow, debt reduction, dividend coverage, and pivotal pipeline readouts.
Reduce confidence if EPS support comes mainly from cost cuts, adjustments, or multiple expansion rather than durable product-level revenue and cash flow.
Investment research summary
Four-master Research Compression
Business essence
Bristol Myers Squibb turns scientific discovery, clinical proof, regulatory approval, payer access, and global commercialization into recurring medicine revenue for serious diseases.
Moat
The moat is strongest where patents, clinical evidence, physician familiarity, reimbursement access, and scale reinforce one another. It narrows when exclusivity expires or rivals show better outcomes, safety, convenience, or price.
Munger risk inversion
The thesis fails if Growth Portfolio medicines cannot outrun legacy erosion, Eliquis economics weaken, acquired assets underperform, payer pressure intensifies, or debt and dividends crowd out R&D flexibility.
Management
Chris Boerner and the board must prove that business development and R&D spending produce durable replacement assets rather than short-lived revenue patches.
Industry trend
Biopharma benefits from aging populations, high unmet need, and scientific progress, but the sector faces pricing scrutiny, patent cliffs, regulatory uncertainty, and binary trial outcomes.
Valuation and margin of safety
BMY trades at a low forward non-GAAP earnings multiple, but the discount is not free. Margin of safety depends on cash flow durability, replacement-product execution, and whether the market is over-discounting the patent cliff.
Source-backed data
BMY Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BMY price | $57.97 at the July 7, 2026 close | StockAnalysis quote snapshot | July 8, 2026 |
| Market capitalization | $118.38 billion, verified as $57.97 x 2.042 billion shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $48.194 billion | BMS 2025 Form 10-K, StockAnalysis, and Macrotrends | July 8, 2026 |
| FY2025 net earnings attributable to BMS | $7.054 billion | BMS 2025 Form 10-K and 2026 proxy cross-check | July 8, 2026 |
| Q1 2026 revenue and non-GAAP EPS | $11.489 billion revenue, $1.58 non-GAAP diluted EPS | BMS Q1 2026 earnings release filed with the SEC | July 8, 2026 |
| 2026 guidance | $46.0 billion to $47.5 billion revenue, $6.05 to $6.35 non-GAAP diluted EPS | BMS Q1 2026 earnings release | July 8, 2026 |
| Cash and cash equivalents | $10.209 billion at FY2025 year-end | BMS 2025 Form 10-K and WSJ balance sheet comparison | July 8, 2026 |
| Total debt and net cash position | $46.43 billion total debt and negative $35.58 billion net cash on a StockAnalysis TTM snapshot | StockAnalysis statistics | July 8, 2026 |
| Valuation check | 9.35x 2026 non-GAAP EPS midpoint, 9.94x FCF per share, 4.35% dividend yield | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day SMA $57.39, 200-day SMA $56.35, 14-day RSI 56.43 | Investing.com technical snapshot | July 8, 2026 |
Frequently Asked Questions
Read the ABBV AI stock analysisView BIIB AI stock forecastExplore TECH AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This BMY AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory events, patent changes, market moves, or macro conditions.